Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences

  1. Ruiz-Sánchez, D.
  2. Peinado, I.I.
  3. Alaguero-Calero, M.
  4. Sastre-Heres, A.J.
  5. Diez, B.G.
  6. Peña-Díaz, J.
Aldizkaria:
Oncology Letters

ISSN: 1792-1082 1792-1074

Argitalpen urtea: 2016

Alea: 12

Zenbakia: 3

Orrialdeak: 1935-1940

Mota: Artikulua

DOI: 10.3892/OL.2016.4871 GOOGLE SCHOLAR lock_openSarbide irekia editor